COVID-19前后间质性肺疾病:双重威胁?
本文讨论既存间质性肺疾病(ILD)和肺纤维化增加COVID-19重症风险,同时COVID-19幸存者可能遗留间质性肺改变和纤维化后遗症。作者呼吁对这类患者进行更密切和标准化的长期随访。
要点
- 既存ILD和肺纤维化增加COVID-19重症风险。
- COVID-19幸存者中观察到残余间质性肺改变和后遗症。
- 需要对COVID-19幸存者进行更密切和标准化的长期随访。
核心结论
- 既存ILD和肺纤维化增加COVID-19重症风险,且COVID-19幸存者可能遗留间质性肺改变和纤维化后遗症,需长期随访。
主要发现
- 既存ILD和肺纤维化增加表现为重症COVID-19的风险。
- 在COVID-19幸存者中观察到残余间质性肺改变和后遗症。
临床怎么用
- 对COVID-19幸存者,尤其既存ILD或肺纤维化者,应进行更密切和标准化的长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pre-existing ILD and pulmonary fibrosis increases the risk to manifest severe COVID-19. Residual interstitial lung changes and sequelae have been observed in COVID-19 survivors. A closer and standardised long-term follow-up of these patients is needed. https://bit.ly/3jWBPCG Sadly, there have already been nearly 200 million confirmed cases of coronavirus disease 2019 (COVID-19) and more than 4 million deaths [1]. The true toll is certainly much higher. We have learned much about the wide spectrum of disease due to COVID-19 over the past 18 months, ranging from asymptomatic infection to severe pneumonia, respiratory failure and death [2]. There is growing concern about whether survivors of COVID-19 will have long-term pulmonary sequelae, including fibrotic interstitial lung disease (ILD) and/or manifest progressive pulmonary fibrosis [3].
引用
- Valenzuela C, Waterer G, Raghu G, et al. Interstitial lung disease before and after COVID-19: a double threat? Eur Respir J. 2021. PMID: 34857587. doi:10.1183/13993003.01956-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。